Pipeline Exits
New stable and affordable COVID vaccine could revolutionize global vaccine distribution
Drug & Vaccine Prototyping
COVID-19 Prototyping
Vaccine
Infectious Diseases
SARS-CoV-2
Licensed to startup company
About the Project
With an expected cost of less than a dollar a dose and no cold-chain required during transport or storage for up to two weeks, including in warm climates, this second-generation vaccine developed by Dr. Peter Kim and his team has the potential to be a game-changer in the fight against COVID-19 and future pandemics, especially in remote and resource-limited settings. Thanks in part to the support they received from the IMA, the Kim lab was able to develop their vaccine rapidly—it took only about four weeks from initial concept to first animal tests. The initial vaccine completed Phase 1 clinical trials in both the United States (NCT05870839) and South Africa (NCT05938075) and is continuing in Phase 2 development by bio-healthcare company Dx&Vx (DXVX).Â
Â
Dr. Kim and his team are now applying their technology to create other pandemic-preparedness vaccines. In October 2025, Dr. Kim was awarded an $18M grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a universal vaccine against the deadly family of flaviviruses that includes Ebola.Â
Â
Recent news
Durable, low-cost COVID-19 vaccine could help fill in gaps around the world
Biochemist Peter Kim receives $18 million grant to develop broadly effective antiviral vaccine
Â
Team
Peter Kim
Principal Investigator
Elizabeth Sefton
Program Manager